Alfred Heart Centre, Alfred Hospital, Melbourne, Australia.
Alfred Heart Centre, Alfred Hospital, Melbourne, Australia -
Minerva Med. 2019 Apr;110(2):121-138. doi: 10.23736/S0026-4806.18.05861-5. Epub 2018 Oct 11.
Despite improved understanding of heart failure (HF) and advances in medical treatments, its prevalence continues to rise, and the role of implantable devices continues to evolve. While cardiac resynchronization therapy (CRT) is an accepted form of treatment for many suffering from HF, there is an ever-evolving body of evidence examining novel indications, optimization of lead placement and device programming, with several competing technologies now also on the horizon. This review aims to take a clinical perspective on the major trials, current indications, controversies and emerging aspects of CRT in the treatment of HF.
尽管对心力衰竭(HF)的认识有所提高,并且医疗治疗也取得了进步,但该病的患病率仍在继续上升,植入式设备的作用也在不断发展。心脏再同步治疗(CRT)虽然是许多 HF 患者公认的治疗方法,但越来越多的证据表明,新型适应证、导线放置和设备编程的优化,以及几种竞争技术也即将出现。本文旨在从临床角度综述 CRT 在 HF 治疗中的主要临床试验、当前适应证、争议和新进展。